New in Cancer: Joint series w/ @AnnSurgOncol on consensus guidelines for managing peritoneal surface malignancies from a multidisciplinary expert panel. 🎥 Watch an intro from @kturaga and explore the full collection: @OncoAlert @YaleMedicine

Learn about Direct to CANCER, our new expedited review process for potentially practice-changing manuscripts that were rejected after peer review by high-impact journals for reasons of scope or priority. More here: @OncoAlert @RamalingamMD

New editorial from @DocBenGlobal comments on recent work from @JenniferPlichta et al comparing survival outcomes for patients with stage III vs de novo stage IV #BreastCancer. @OncoAlert #BCSM

"In precision oncology, we must ensure BIPOC and trans communities aren't left behind. Collect the data, inform the research, and create better guidelines.". Listen to a recent episode of CancerSpeak w/ @DrMoniqueGary: @OncoAlert

Are transplant strategies in relapsed myeloma relevant in the cellular treatment era? Drs. Despina Fotiou and Efstathios Kastritis of the University of Athens comment on recent work from Heinz Ludwig MD et al. @oncoalert @IMFmyeloma @uoaofficial #mmsm

.@cityofhope researcher Pamela S. Becker MD, PhD comments on the recent retrospective study by @DrHKantarjian et al evaluating outcomes in newly diagnosed FLT3-mutated #AML across treatment regimens. @OncoAlert #leusm

New review | The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk. @yueliao0 @cityofhope @UTArlington @OncoAlert

Limited evidence exists regarding QOL losses experienced by informal cancer caregivers. New #OpenAccess work led by @DHE_Deakin researchers investigates annual opportunity costs, projected informal care costs, and QALE gaps. @OncoAlert

According to a recent study in NEJM, imlunestrant conferred significantly longer progression-free survival than standard therapy to patients with advanced breast cancer with ESR1 mutations. Read our latest CancerScope for the full story: @OncoAlert

Thank you to our friends at @OncoAlert for highlighting the recent publication by @EChrisDee et al that sheds light on palliative care receipt disparities among Hispanic populations. Read it here:

The benefit of adjuvant dose-dense chemotherapy in patients with node-positive breast cancer is sustained after a 12-year follow-up according to a recently publish trial. Our latest CancerScope explores the findings: @OncoAlert

New in CancerScope 🔎 FDA approves durvalumab for perioperative immunotherapy for patients with muscle-invasive bladder cancer In a prespecified analysis, the trial demonstrated a statistically significant improvement in EFS and OS. @OncoAlert

New and #OpenAccess 🔓 This article provides an overview of the data included in INSTRuCT database and its potential to be used for future analyses. @OncoAlert #sarcoma #rhabdomyosarcoma

New editorial by @kturaga | Intraperitoneal paclitaxel for peritoneal metastases from gastric cancer in Western populations. @OncoAlert

There was no clinically relevant difference in safety between FRC and ASI as measured by the primary endpoint in either study; odds ratio (95% CI) of 0.87 (0.30–2.49) and 1.0 (0.30–3.39) for CheckMate 742 and CheckMate 800, respectively. @OncoAlert

New & available #OpenAccess | Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 study. @OncoAlert @AjaiChari CC: @AjayNookaMD #mmsm

Improved awareness of sexual dysfunction prevalence and risk factors in male childhood cancer survivors can help clinicians better assess and treat those at highest risk. @OncoAlert @ATLPedsHemOnc

Top advances in CAR-T cell therapy for neuro-oncology from the past year include:. ✅ GD2-CAR T cells in DMG.✅ Bivalent EGFR/IL13Rα2 CAR T cells.✅ CARv3-TEAM-E BiTE secreting CAR T. @OncoAlert @Ravi_Medikonda1 @Matthewabii @Ethan_Schonfeld @MichaelLimMD

#OpenAccess! 🔓 This is the largest study of survival outcomes of pulmonary metastasis–directed local therapy (PM-LT) in metastatic adenoid cystic carcinoma (ACC). Findings suggest PM-LT does not increase overall survival in unselected ACC. @OncoAlert

MRI-assisted biopsy shows poor sensitivity for detecting cribriform #ProstateCancer & IDC in patients with GG2–3 PCa. This work supports improving detection of variant histologies via optimized biopsy, imaging, and biomarkers. @Adam_Weiner535 @OncoAlert

This review led by @DrHKantarjian summarizes relevant information concerning the management of CML in 2025, and addresses some CML treatment pathways that became entrenched in the management of CML in the first 15–20 years of TKI experience. @OncoAlert.